Publicacións nas que colabora con Angeles Castro Iglesias (17)

2023

  1. Renal profile of patients treated with elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort

    European Journal of Hospital Pharmacy, Vol. 30, Núm. 4, pp. 221-226

2022

  1. Discontinuation due to neuropsychiatric adverse events with efavirenz-and dolutegravir-based antiretroviral therapy: a comparative real-life study

    European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 207-211

2020

  1. Epidemiology and outcome of HIV-infected patients admitted to the ICU in the current highly active antiretroviral therapy era

    Medicina Intensiva, Vol. 44, Núm. 5, pp. 283-293

2019

  1. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis c virus infected patients. Results in real clinical practice

    Revista Espanola de Quimioterapia, Vol. 32, Núm. 2, pp. 137-144

  2. Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines

    Journal of the International Association of Providers of AIDS Care, Vol. 18

  3. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine

    Basic and Clinical Pharmacology and Toxicology, Vol. 124, Núm. 4, pp. 479-490

2018

  1. Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors

    AIDS, Vol. 32, Núm. 1, pp. 121-125

2017

  1. Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure

    Journal of Medical Virology, Vol. 89, Núm. 7, pp. 1304-1308

  2. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance

    Basic and Clinical Pharmacology and Toxicology, Vol. 121, Núm. 5, pp. 442-446

  3. Increased incidence of cancer observed in HIV/hepatitis C virus-coinfected patients versus HIV-monoinfected

    AIDS, Vol. 31, Núm. 8, pp. 1099-1107

  4. Plasma mitochondrial DNA levels are inversely associated with HIV-RNA levels and directly with CD4 counts: Potential role as a biomarker of HIV replication

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 11, pp. 3159-3162

  5. Tendencia de las hospitalizaciones, reingresos y mortalidad intrahospitalaria en los pacientes infectados por VIH entre 1993-2013: impacto de la coinfección por el virus de la hepatitis C

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 35, Núm. 1, pp. 20-26

2016

  1. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 4, pp. 1051-1055

  2. Long-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain

    Journal of Medical Virology, Vol. 88, Núm. 12, pp. 2125-2131

2015

  1. Trends on epidemiological, virological, and clinical features among newly diagnosed HIV-1 persons in Northwest Spain over the last 10 years

    Journal of Medical Virology, Vol. 87, Núm. 8, pp. 1319-1326

2014

  1. High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment response

    AIDS, Vol. 28, Núm. 12, pp. 1837-1840

  2. Seroprevalence of HCV and HIV infections by year of birth in Spain: Impact of US CDC and USPSTF recommendations for HCV and HIV testing

    PLoS ONE, Vol. 9, Núm. 12